Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons

Lim, Aaron G.; Stone, Jack; Hajarizadeh, Behzad; Byrne, Marianne; Chambers, Georgina M.; Martin, Natasha K.; Grebely, Jason; Dore, Greg; Lloyd, Andrew R.; Vickerman, Peter

doi:10.1002/hep.32002

Cited by 10 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This step is essential for determining whether the assumptions underlying our mechanistic models, which link scale-up in HCV interventions to changes in HCV prevalence and incidence, are accurate. A recent study conducted in an Australian prison setting lends some support to our findings, as our modelled projections of HCV incidence following the scale-up of HCV treatment were found to be very similar to observed data [77] .…”

Section: Other Indicatorssupporting

confidence: 89%

Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO

Artenie¹,

Luhmann²,

Lim³

et al. 2022

The Lancet Gastroenterology & Hepatology

Self Cite

View full text Add to dashboard Cite

Section: Other Indicatorssupporting

confidence: 89%

Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO

Artenie¹,

Luhmann²,

Lim³

et al. 2022

The Lancet Gastroenterology & Hepatology

Self Cite

View full text Add to dashboard Cite

“…Multiple modeling studies reported that curative treatment of HCV in the prison population could lead to a decrease in prevalence in the general population [29][30][31][32]. These studies underline the importance of screening and DAA therapy programs in the prison populations.…”

Section: Discussionmentioning

confidence: 92%

Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents

Werling

Hunyady

Makara

et al. 2022

Viruses

View full text Add to dashboard Cite

A hepatitis C virus (HCV) screening and treatment program was conducted in Hungarian prisons on a voluntary basis. After HCV-RNA testing and genotyping for anti-HCV positives, treatments with direct-acting antiviral agents were commenced by hepatologists who visited the institutions monthly. Patients were supervised by the prisons’ medical staff. Data were retrospectively collected from the Hungarian Hepatitis Treatment Registry, from the Health Registry of Prisons, and from participating hepatologists. Eighty-four percent of Hungarian prisons participated, meaning a total of 5779 individuals (28% of the inmate population) underwent screening. HCV-RNA positivity was confirmed in 317/5779 cases (5.49%); 261/317 (82.3%) started treatment. Ninety-nine percent of them admitted previous intravenous drug use. So far, 220 patients received full treatment and 41 patients are still on treatment. Based on the available end of treatment (EOT) + 24 weeks timepoint data, per protocol sustained virologic response rate was 96.8%. In conclusion, the Hungarian prison screening and treatment program, with the active participation of hepatologists and the prisons’ medical staff, is a well-functioning model. Through the Hungarian experience, we emphasize that the “test-and-treat” principle is feasible and effective at micro-eliminating HCV in prisons, where infection rate, as well as history of intravenous drug usage, are high.

show abstract

“…Clinicians should consider treatment adherence as well as ongoing risk behaviour for HCV reinfection. 33,34 Reinfection should not be a barrier to re-treatment -see the full NPHN Consensus statement for further detail. 15 More information about the assessment and management of nonresponse versus reinfection is available in the Australian HCV infection management consensus statement.…”

Section: Treatment Non-response Versus Hcv Reinfectionmentioning

confidence: 99%

“…In people with detectable HCV RNA after treatment, it is important to try and distinguish treatment non‐response from HCV reinfection, as this distinction influences the DAA re‐treatment plan. Clinicians should consider treatment adherence as well as ongoing risk behaviour for HCV reinfection 33,34 . Reinfection should not be a barrier to re‐treatment — see the full NPHN Consensus statement for further detail 15 .…”

Section: Consensus Recommendationsmentioning

confidence: 99%

Consensus recommendations on the management of hepatitis C in Australia's prisons

Winter

Sheehan

Papaluca

et al. 2023

Medical Journal of Australia

View full text Add to dashboard Cite

Introduction:Prison settings represent the highest concentration of prevalent hepatitis C cases in Australia due to the high rates of incarceration among people who inject drugs. Highly effective direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection are available to people incarcerated in Australian prisons. However, multiple challenges to health care implementation in the prison sector present barriers to people in prison reliably accessing hepatitis C testing, treatment, and prevention measures.

show abstract

Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP‐C Treatment as Prevention Study in Prisons

Abstract: The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Cited by 10 publications

References 34 publications

Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO

Methods and indicators to validate country reductions in incidence of hepatitis C virus infection to elimination levels set by WHO

Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents

Consensus recommendations on the management of hepatitis C in Australia's prisons

Contact Info

Product

Resources

About